Streetbeat News

Products Services

ASLN

ASLAN Pharmaceuticals announced that the eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:25 pm

SKYE

Skye Bioscience, Inc. (OTCQB:SKYE) has completed the production of its cannabinoid-based drug, SBI-100, for a planned phase 2a study of glaucoma and ocular hypertension. The production was carried out by its contract manufacturer, NextPharma Oy, in Finland. The company is now working on additional logistical and preparatory steps to start the study, which is expected to begin enrollment in the third quarter.

Portfolio Pulse from Vuk Zdinjak

July 06, 2023 | 12:23 pm

MIGI

Mawson Infrastructure Group Inc. (NASDAQ:MIGI) has secured a new mining site in Bellefonte, Pennsylvania, which is already operational with approximately 2,600 miners. The site has 8 MW of immediately available power and can be expanded by an additional 16 MW. The company plans to use the site as a 100% self-mining facility and a testing facility for the latest generation ASIC designs and hardware.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:22 pm

BDRX

Biodexa Pharmaceuticals has published the results of its Phase I study PNOC015 of MTX110 in the treatment of pediatric patients with DMG. The study demonstrated an acceptable safety profile and encouraging efficacy, with a median overall survival of 26.1 months, compared to historical data of 10.0 months.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:18 pm

CRBU

GENI

KZIA

Kazia Therapeutics' Paxalisib has received fast-track designation from the FDA for treatment of solid tumor brain metastases, leading to a 39% increase in KZIA's stock. Caribou Biosciences received a $25 million equity investment from Pfizer, resulting in a 22% increase in CRBU's stock. The NFL extended its strategic partnership with Genius Sports, causing a 26% increase in GENI's stock.

Portfolio Pulse from ryanfaloona@benzinga.com

July 06, 2023 | 12:18 pm

AMRC

Ameresco, Inc. (NYSE:AMRC) has secured four contracts for Battery Energy Storage System (BESS) projects with Middle River Power (MRP) at California gas power plants. The projects, which will add 379 megawatt-hours to the California grid, are designed to enhance the efficiency of MRP's natural gas power plants and support California's goal of 100% renewable energy by 2045. The work is expected to start in Summer 2023 and be completed by Q3 2024.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:16 pm

BKR

NEXT

Baker Hughes (NASDAQ:BKR) has been awarded a contract by Bechtel Energy Inc. to supply three Main Refrigerant Compressors (MRCs) for NextDecade's Rio Grande LNG project in Texas. The technology is capable of producing a nameplate capacity of approximately 17.61 million tonnes per annum (MTPA). This follows another recent contract awarded by Bechtel to Baker Hughes to supply two liquefaction trains for another LNG project in Texas.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:15 pm

AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced that it will present positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm, an epinephrine sublingual film, at the Global Food Allergy Prevention Summit. If approved, Anaphylm could be the first oral candidate for the emergency treatment of severe allergic reactions, including anaphylaxis.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:11 pm

RARE

Ultragenyx Pharmaceutical Inc. has announced that the first patients have been dosed in a Phase 3 program evaluating Setrusumab for the treatment of Osteogenesis Imperfecta.

Portfolio Pulse from Benzinga Newsdesk

July 06, 2023 | 12:11 pm

VXRT

Vaxart, Inc. (NASDAQ:VXRT) announced positive preliminary topline data from the Phase 2 clinical trial of its oral pill bivalent norovirus vaccine candidate. The vaccine met all primary endpoints, showing robust serum immune responses across all doses. The company expects topline data from Phase 2 GI.1 challenge study in Q3 2023. The data will inform dosage levels in a larger Phase 2b study and support an End-of-Phase 2 meeting with the FDA.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 12:08 pm